Freedom of information (FOI) releases from MHRA

This is a disclosure log of Medicines and Healthcare products Regulatory Agency's responses to freedom of information (FOI) or environmental information regulations (EIR) requests that might be of wider public interest.

If you can't find the information you're looking for, you can make a new FOI request.

Filters

Clear filters

  • Keywords filters

  • Year filters

  • Month filters

1,836 disclosures

  1. PAR for Remeron oral solution 15 mg/ml -MAH: Organon Laboratories Ltd.

    We would like to request a copy of the Public Assessment report (UK PAR) and information if its Initial application or MA transferred application of the following product under the Freedom of Information Act (FOIA) of MHRA: Product name: Remeron oral solution 15 mg/ml MAH name: Organon Laboratories Ltd, Cambridge Science Park, Milton Road, Cambridge, CB4 0FL United Kingdom PL number: not known

    Published: 14 April 2026

  2. Public Assessment Report (PAR) – PL 20416/0010–0011 (For MAH Records)

    I am writing on behalf of Crescent Pharma Limited, Marketing Authorisation Holder for Amoxicillin 125mg/5ml Oral Suspension and Amoxicillin 250mg/5ml Oral Suspension (PL 20416/0010-0011). We kindly request a copy of the Public Assessment Report (PAR) for the above-mentioned Marketing Authorisation. The requested documentation is required for our internal regulatory records and product lifecycle management purposes. We confirm that Crescent Pharma Limited is the current MAH for these licences. Should you require any formal confirmation, authorisation documentation, or completion of a specific request form, please let us know. We would appreciate confirmation of receipt of this request and details of any applicable process or timeline for provision of the PAR.

    Published: 14 April 2026

  3. PAR for Mirtazapine 15 mg/ml oral solutions-PL 00427/0241

    We would like to request a copy of the Public Assessment report (UK PAR) and information if its Initial application or MA transferred application of the following product under the Freedom of Information Act (FOIA) of MHRA: Product name: Mirtazapine 15 mg/ml oral solution MAH name: Rosemont Pharmaceuticals Ltd Rosemont House Yorkdale Industrial Park Braithwaite Street Leeds LS11 9XE UK PL number: PL 00427/0241

    Published: 14 April 2026

  4. Puberty blockers

    I would like to pursue your suggestion that the request is limited to part 2 of my request.

    Published: 14 April 2026

  5. Requesting information surrounding the research peptide Retatrutide.

    I would like all available information for the following: 1.) The regulations currently in place for the research peptide Retatrutide. 2.) Any information on human/animal trials of Retatrutide taking place. 3.) Any communications surrounding the use of Retatrutide on humans. 4.) Any information held about the Criminal Enforcement Unit seizing units of Retatrutide. 5.) Any communications about the sale of Retatrutide.

    Published: 14 April 2026

  6. Requesting information surrounding the research peptide MT2

    I would like all available information for the following: 1.) The regulations currently in place for the research peptide MT2. 2.) Any information on human/animal trials of MT2 taking place. 3.) Any communications surrounding the use of MT2 on humans. 4.) Any information held about the Criminal Enforcement Unit seizing units of MT2. 5.) Any communications about the sale of MT2.

    Published: 14 April 2026

  7. Requesting information surrounding the research peptide GHK-CU

    I would like all available information for the following: 1.) The regulations currently in place for the research peptide GHK-CU. 2.) Any information on human/animal trials of GHK-CU taking place. 3.) Any communications surrounding the use of GHK-CU on humans. 4.) Any information held about the Criminal Enforcement Unit seizing units of GHK-CU. 5.) Any communications about the sale of GHK-CU.

    Published: 14 April 2026

  8. Labelling text for Evana 500 mg tablets (tranexamic acid) PL 14251/0300

    Please could I be sent a copy of the MHRA registered labelling text for Evana 500 mg tablets (tranexamic acid) PL 14251/0300.

    Published: 14 April 2026

  9. Public assessment report for Urospir™ 50 mg/5 ml Oral Solution

    We are developing generic formulation for Spironolactone 50mg/ 5 ml oral solution.SPC and PIL information is available for Urospir™ 50 mg/5 ml Oral Solution on MHRA website. We would like to know basis for approval for Urospir™ 50 mg/5 ml Oral Solution hence requesting you to share public assessment of Urospir™ 50 mg/5 ml Oral Solution.

    Published: 14 April 2026

  10. Correspondence - the campaign groups Sex Matters or the LGB Alliance

    I would like to request the following information, as a Freedom of Information request. 1. In the past 12 months, has any representative of the Medicines and Healthcare products Regulatory Agency (MHRA) had any meetings – face to face or virtual – with any representative/s of the campaign groups Sex Matters or the LGB Alliance? 2. If so, how many meetings have taken place and with representative/s of which organisation? 3. Were minutes taken at these meetings? 4. If so, please share these minutes. 5. In the past 12 months, has any representative of the Medicines and Healthcare products Regulatory Agency (MHRA) sent or received any correspondence – including emails, printed letters or ‘app chats’ (e.g., WhatsApp) - with any representative/s of the campaign groups Sex Matters or the LGB Alliance? 6. If so, how much correspondence has taken place (e.g., how many emails have been sent from each organisation, including replies) and with representative/s of which organisation? 7. If so, please share the correspondences.

    Published: 14 April 2026